Precigen Stock Price, News & Analysis (NASDAQ:PGEN) $1.18 +0.01 (+0.85%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$1.14▼$1.2150-Day Range$0.89▼$1.4252-Week Range$0.81▼$2.29Volume832,960 shsAverage Volume1.82 million shsMarket Capitalization$293.73 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Precigen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside747.5% Upside$10.00 Price TargetShort InterestBearish12.67% of Float Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$35,250 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.34) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector568th out of 954 stocksPharmaceutical Preparations Industry202nd out of 362 stocks 3.4 Analyst's Opinion Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Precigen has a forecasted upside of 747.5% from its current price of $1.18.Amount of Analyst CoveragePrecigen has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.67% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently increased by 2.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Precigen is -0.77. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 6 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,250.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.70% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.48% of the stock of Precigen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.34) to ($0.28) per share.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Precigen Stock (NASDAQ:PGEN)Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Read More PGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGEN Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comPrecigen to Participate in the JMP Securities Hematology and Oncology SummitNovember 22, 2023 | morningstar.comPrecigen Inc PGENDecember 9, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 11, 2023 | markets.businessinsider.comPromising Pipeline Progress and Strong Financial Standing Justify Buy Rating for PrecigenNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Precigen (PGEN)November 9, 2023 | msn.comPrecigen GAAP EPS of -$0.08 in-line, revenue of $1.38M misses by $0.6MNovember 9, 2023 | finance.yahoo.comPrecigen Reports Third Quarter 2023 Financial Results and Progress of Clinical ProgramsNovember 7, 2023 | finance.yahoo.comPrecigen to Participate in the Stifel 2023 Healthcare ConferenceDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 21, 2023 | uk.finance.yahoo.comPrecigen, Inc. (PGEN)September 25, 2023 | finance.yahoo.comWhile institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownershipSeptember 19, 2023 | finance.yahoo.comPrecigen to Participate in Upcoming Leading Investor and Industry ConferencesSeptember 5, 2023 | finance.yahoo.comShould You Buy Precigen, Inc. (PGEN) After Golden Cross?August 25, 2023 | finance.yahoo.comIs Precigen Inc Set to Underperform? Analyzing the Factors Limiting GrowthAugust 25, 2023 | finance.yahoo.comIs Precigen (PGEN) Significantly Overvalued? A Comprehensive Valuation AnalysisAugust 17, 2023 | benzinga.comPrecigen Recent Insider ActivityAugust 17, 2023 | finance.yahoo.comFred Hassan Bought 185% More Shares In PrecigenAugust 13, 2023 | markets.businessinsider.comPrecigen (PGEN) Receives a Buy from Stifel NicolausAugust 11, 2023 | finance.yahoo.comHere's Why We're Watching Precigen's (NASDAQ:PGEN) Cash Burn SituationAugust 10, 2023 | msn.comHC Wainwright & Co. Reiterates Precigen (PGEN) Buy RecommendationAugust 10, 2023 | finance.yahoo.comPGEN - Precigen, Inc.August 10, 2023 | markets.businessinsider.comPrecigen (PGEN) Receives a Buy from H.C. WainwrightAugust 9, 2023 | seekingalpha.comPrecigen, Inc. (PGEN) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | msn.comPrecigen Phase 1/2 trial selected as a pivotal study for rare disease therapyAugust 9, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Precigen (PGEN)August 9, 2023 | seekingalpha.comPrecigen Q2 2023 Earnings PreviewAugust 9, 2023 | finance.yahoo.comPrecigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025See More Headlines Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PGEN CUSIPN/A CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees209Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$14.00 Low Stock Price Target$6.00 Potential Upside/Downside+747.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$28.32 million Net Margins-1,257.75% Pretax Margin-1,259.50% Return on Equity-54.48% Return on Assets-39.74% Debt Debt-to-Equity RatioN/A Current Ratio2.83 Quick Ratio2.83 Sales & Book Value Annual Sales$6.76 million Price / Sales43.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book2.36Miscellaneous Outstanding Shares248,919,000Free Float145,120,000Market Cap$293.72 million OptionableOptionable Beta1.80 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Randal J. Kirk J.D. (Age 70)Executive Chairman Comp: $100kDr. Helen Sabzevari MPH (Age 61)Ph.D., President, CEO & Director Comp: $1.29MMr. Harry Thomasian Jr. (Age 60)Chief Financial Officer Comp: $524.04kMr. Rutul R. Shah (Age 42)Chief Operating Officer Comp: $393.54kMr. Donald P. Lehr (Age 48)Chief Legal Officer & Corporate Secretary Comp: $652.4kMr. Jeffrey Thomas Perez (Age 51)Senior Vice President of Intellectual Property Affairs Comp: $570.24kDr. Thomas D. Reed Ph.D. (Age 57)Founder & Chief Science Officer Comp: $572.72kMr. Steven HarasymVP & Head of Investor RelationsMarie RossiVice President of CommunicationsMr. Rob RussellVP & Head of Human ResourcesMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCKalVista PharmaceuticalsNASDAQ:KALVGeneluxNASDAQ:GNLXUroGen PharmaNASDAQ:URGNAC ImmuneNASDAQ:ACIUView All CompetitorsInsiders & InstitutionsGraham Capital Management L.P.Sold 16,693 shares on 11/22/2023Ownership: 0.008%Jacobs Levy Equity Management Inc.Sold 666,781 shares on 11/17/2023Ownership: 0.276%GSA Capital Partners LLPBought 334,789 shares on 11/15/2023Ownership: 0.134%AQR Capital Management LLCSold 56,222 shares on 11/15/2023Ownership: 0.035%The Manufacturers Life Insurance Company Bought 50,671 shares on 11/15/2023Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions PGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Precigen stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares. View PGEN analyst ratings or view top-rated stocks. What is Precigen's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 747.5% from the stock's current price. View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts. How have PGEN shares performed in 2023? Precigen's stock was trading at $1.52 at the start of the year. Since then, PGEN stock has decreased by 22.4% and is now trading at $1.18. View the best growth stocks for 2023 here. When is Precigen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our PGEN earnings forecast. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The biotechnology company had revenue of $1.38 million for the quarter, compared to the consensus estimate of $2.68 million. Precigen had a negative net margin of 1,257.75% and a negative trailing twelve-month return on equity of 54.48%. What ETF holds Precigen's stock ? Virtus LifeSci Biotech Clinical Trials ETF holds 87,692 shares of PGEN stock, representing 0.90% of its portfolio. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC). Who are Precigen's major shareholders? Precigen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Iridian Asset Management LLC CT (0.81%), Northern Trust Corp (0.44%), Charles Schwab Investment Management Inc. (0.42%), Jacobs Levy Equity Management Inc. (0.28%), Bank of New York Mellon Corp (0.18%) and Fore Capital LLC (0.17%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Rutul R Shah, Steven Frank and Trading SA Ares. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PGEN) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.